CTRI/2020/05/025063
Completed
Phase 2
A pre experimental study to assess the impact of culturally appropriate and theoretically driven Nurse Led Counselling Intervention given to parents of children with Cerebral Visual Impairment (CVI) on adherence to eye activities attending Advanced Eye Centre at PGIMER, Chandigarh,2019-21
ational Institute of Nursing Education PGIMER SEC Chandigarh0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: H475- Disorders of other visual pathways
- Sponsor
- ational Institute of Nursing Education PGIMER SEC Chandigarh
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children with CVI between the age of 3 month\-12 years registered since 2018 onwards in AEC OPD at PGIMER, Chandigarh after August 2020 onwards.
Exclusion Criteria
- •Children with other Congenital anomalies along with CVI, who require immediate medical care.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A prospective study to investigate the effect of CBM558 combined with pembrolizumab on gut microbiota and prognosis in patients with advanced urothelial carcinoma.JPRN-jRCTs031220689Taguchi Satoru30
Active, not recruiting
Not Applicable
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2011-005710-11-DEOXXON Pharma AG75
Active, not recruiting
Not Applicable
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2011-005710-11-CZOXXON Pharma AG75
Active, not recruiting
Not Applicable
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2011-005710-11-HUOXXON Pharma AG75
Active, not recruiting
Not Applicable
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriaEUCTR2011-005710-11-PLOXXON Pharma AG75